Pulse Biosciences PLSE 深 滬
已收盤 08-07 16:00:00 美东时间
42.41
+4.170
+10.90%
華盛通- 最 高45.90
- 今 開37.84
- 成交量 73.46万股
- 最 低 37.40
- 昨 收 38.24
- 總市值 29.35亿
- 52周最高 45.90
- 市盈率 靜 --
- 換手率 1.06%
- 52周最低 12.56
- 委 比 16.94%
- 總股本 6920.97万
- 歷史最高 45.90
- 量 比 2.51
- 振 幅 22.23%
- 歷史最低 1.18
- 每 手 1
- 風險率 5.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pulse Biosciences shares are trading lower after the company reported worse-than-expected Q2 sales results.
Pulse Biosciences shares are trading lower after the company reported worse-than-expected Q2 sales results.
08-07 04:36
Biotech stocks lead healthcare's overbought list as earnings picks up
Healthcare stocks are in focus as second-quarter earnings season shifts into high gear, with investors evaluating whether recent rallies across biotech, medical technology and healthcare services can ...
07-23 19:18
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Friday. Shares of Apogee Enterprises Inc (NASDAQ:APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Adjusted diluted earnings came in at 57 cents per share, topping the a...
06-26 22:18
美股大行评级 | 绩后暴跌，博通仍获11家大行上调目标价；CrowdStrike获21家大行集体上调目标价；Netskope、Veeva Systems惨遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Vivos Therapeutics"买入"评级，目标价从3美元升至3.1美元；富国银行：维持Veeva Systems"超配"评级，目标价从317美元升至320美元
06-05 11:33
Canaccord Genuity Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $32
Canaccord Genuity analyst William Plovanic initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $32.
06-04 23:18
Pulse Biosciences shares are trading higher after its Co-Chairmen purchased approximately $13.3 million worth of shares.
Pulse Biosciences shares are trading higher after its Co-Chairmen purchased app...
05-13 00:14
Pulse Biosciences Co‑Chairmen, CEO Purchase ~$13.3M In Shares Via ATM Program
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and
05-12 19:22
电话会总结 ｜ Pulse Biosciences(PLSE)2025财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Pulse Biosciences业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金状况：** 截至2025年3月31日，现金及现金等价物为1.193亿美元，较2024年同期的3,490万美元大幅增长，较2024年年末增加120万美元。第一季度通过认股权证行权获得1,410万美元收入。 **成本费用：** GAAP总成本和费用为1,800万美元，较上年同期的1,060万美元增加740万美元。非现金股票薪酬费用为570万美元，较上年同期的180万美元大幅增加390万美元。 **净亏损：** GAAP净亏损为1,680万美元，较上年
05-05 12:26
Earnings Scheduled For May 4, 2026
Companies Reporting Before The Bell • Pulse Biosciences (NASDAQ:PLSE) is likely...
05-04 19:11
Pulse Biosciences Q1 EPS $(0.27) Beats $(0.32) Estimate, Sales $401.000K Beat $400.000K Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.32) by 12.9 percent. This is a 8 percent decrease over losses of $(0.25) per share from the
05-04 19:09
